Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016 - Product Image

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016

  • ID: 4035458
  • Report
  • 56 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • Nyken BV
  • RESprotect GmbH
  • MORE
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016

Summary

‘Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016’, provides in depth analysis on Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted pipeline therapeutics.

The report provides comprehensive information on the Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1)
- The report reviews Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • Nyken BV
  • RESprotect GmbH
  • MORE
Introduction

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) Overview

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Stage of Development

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Therapy Area

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Indication

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Companies

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Companies Involved in Therapeutics Development

Arno Therapeutics Inc

Nyken BV

Oncogenex Pharmaceuticals Inc

RESprotect GmbH

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Drug Profiles

apatorsen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brivudine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYK-1112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYK-1341 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Dormant Projects

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Discontinued Products

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Featured News & Press Releases

Oct 25, 2016: OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2 Trial in Metastatic Bladder Cancer

Mar 01, 2016: RedHill Biopharma Provides Update on RP101

Jan 20, 2016: OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer

Dec 09, 2015: OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis

Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis

Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

Sep 30, 2015: OncoGenex Announces Completion of Patient Enrollment in Borealis-2 Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition

Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015

Jun 01, 2015: OncoGenex Announces Data from Borealis-1 Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

May 20, 2015: OncoGenex To Present Phase II Study Data On Apatorsen At ASCO 2015 Annual Meeting

May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Arno Therapeutics Inc, H2 2016

Pipeline by Nyken BV, H2 2016

Pipeline by Oncogenex Pharmaceuticals Inc, H2 2016

Pipeline by RESprotect GmbH, H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Arno Therapeutics Inc
  • Nyken BV
  • Oncogenex Pharmaceuticals Inc
  • RESprotect GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll